[
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]